U.S. Markets open in 3 hrs 8 mins

Laboratorios Farmaceuticos ROVI, S.A. (ROVI.MC)

MCE - MCE Delayed Price. Currency in EUR
Add to watchlist
15.72-0.28 (-1.75%)
As of 5:35PM CEST. Market open.

Laboratorios Farmaceuticos ROVI, S.A.

C/ Julián Camarillo, 35
Madrid 28037
34 91 375 62 30

Full Time Employees1,170

Key Executives

Mr. Juan López-Belmonte LópezChairman & Chief Exec. Mang.150kN/AN/A
Mr. Juan López-Belmonte EncinaChief Exec. Mang. & Director521kN/AN/A
Mr. Iván López-Belmonte EncinaFirst VP412kN/AN/A
Mr. Javier López-Belmonte EncinaSecond VP & CFO400kN/AN/A
Mr. Fernando Martínez MoralesDirector of SalesN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Laboratorios Farmaceuticos Rovi, S.A. produces and sells pharmaceutical products in Spain and internationally. The company’s principal product is Bemiparin, a low molecular weight heparin. Its prescription products comprise Hibor to prevent thromboembolic disease; Osseor to treat osteoporosis; Hepadren to prevent clotting in the extracorporeal circuit; Hirobriz and Ulunar Breezhaler for chronic obstructive pulmonary disease; Medicebran and Medikinet for attention deficit and hyperactivity disorder in children and teenagers; Glufan for relieving symptoms of degenerative osteoarthritis (OA); and Corlentor for coronary artery disease and chronic heart failure. The company’s prescription products also include Exxiv for the symptoms of OA, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis; Calcio y Vitamina D3 ROVI for osteoporosis; Bertanel for adults active rheumatoid, juvenile idiopatic, and psoriatic arthritis; Vytorin, Orvatez, and Absorcol for hypercholesterolaemia; Siklos for the prevention of recurrent and painful vaso-occlusive crises; Thymanax for depressive episodes in adults; and Volutsa to treat benign prostatic hyperplasia. In addition, it offers diagnostic products, such as SonoVue for use in ultrasound imaging; Iopamiro and Iomeron radiographic contrast media for diagnosis; and Multihance and Prohance for use in diagnostic magnetic resonance imaging. Further, the company provides OTC products comprising Perspirex to control sweating from the underarms; Enerzona, a protein product; Dentimelo to repair oral mucosal lesions and gums; ColdPack cold and hot bag for reliving pain; and Nitview Ledcomb, a product for lice and nits. Additionally, it distributes products licensed from other laboratories. The company was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Corporate Governance

Laboratorios Farmaceuticos ROVI, S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.